Gerresheimer Secures Financial Reprieve and Rejects Suitor in Turnaround Push

Gerresheimer wins creditor support to extend debt deadlines and suspends covenants, while rejecting a takeover approach. Shares surge 18% as the company focuses on a major restructuring.

Investors in Gerresheimer breathed a collective sigh of relief on Friday as the packaging specialist executed a critical two-part maneuver. The company not only secured a vital debt extension from its creditors but also publicly fended off an unsolicited takeover approach, sending its shares soaring by nearly 18 percent to close at EUR 20.82.

The immediate financial pressure has been alleviated after noteholders, with a 96 percent majority, agreed to extend the deadline for the audited 2025 annual report to the end of September 2026. This agreement covers the total debt volume of EUR 870 million. Crucially, banking partners have also consented to suspend key financial covenants related to leverage ratios until at least the third quarter, removing the imminent threat of a covenant breach.

Management, however, does not intend to use the full grace period. The board aims to publish the certified financial statements for 2025 as early as June. This will be swiftly followed by the delayed first-quarter results. Any further postponement beyond this internal target would jeopardize the newly negotiated peace with lenders.

Parallel to the financial restructuring, Gerresheimer is aggressively streamlining its operations. The company has officially launched the sale process for its US subsidiary, Centor Inc., and is moving to shut down its plant in Chicago Heights. Both measures are slated for completion by the end of 2026. The Centor divestment is already attracting significant interest, with a double-digit number of potential buyers currently conducting due diligence.

The drastic restructuring is a direct response to an accounting scandal that triggered the current crisis. The company admitted to improperly recognizing approximately EUR 35 million in revenue related to so-called "bill-and-hold" agreements, a clear violation of IFRS standards. Germany's financial regulator, BaFin, is now investigating this issue along with other concerns, including the accounting treatment of leasing liabilities, capitalized development costs, and assets worth hundreds of millions of euros.

This profound uncertainty has fueled extreme volatility in the stock. The annualized 30-day volatility remains elevated above 110 percent, reflecting deep-seated investor nerves. While Friday's rally delivered a weekly gain of over 21 percent, the stock is still down almost 25 percent since the start of the year, with a year-to-date loss approaching 60 percent. This steep decline led to the company's expulsion from the SDAX index in mid-April.

Amid this turmoil, US competitor Silgan saw an opportunity and made a takeover approach. Gerresheimer's board promptly rejected the offer, the details of which were not disclosed. This swift rebuff signals management's determination to steer its own turnaround and refocus on its core pharmaceutical packaging business.

The path ahead is clearly defined. Executing the Centor sale, finalizing the plant closure, and delivering clean audited accounts by June are the immediate priorities. The creditor reprieve has bought valuable time, but the company remains firmly in turnaround mode, with its recovery contingent on flawless execution in the coming months.